Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Journal of Virology
Iain StephensonKarl G Nicholson

Abstract

Trivalent influenza virus A/Duck/Singapore (H5N3), A/Panama (H3N2), and B/Guandong vaccine preparations were used in a randomized, controlled, dose-ranging phase I study. The vaccines were prepared from highly purified hemagglutinin and neuraminidase from influenza viruses propagated in embryonated chicken eggs and inactivated with formaldehyde. We assigned 100 participants to six vaccine groups, as follows. Three intranasally vaccinated groups received 7.5-microg doses of hemagglutinin from each virus strain with either 3, 10, or 30 microg of heat-labile Escherichia coli enterotoxin (LTK63) and 990 microg of a supramolecular biovector; one intranasally vaccinated group was given 7.5-microg doses of hemagglutinin with 30 microg of LTK63 without the biovector; and another intranasally vaccinated group received saline solution as a placebo. The final group received an intramuscular vaccine containing 15 microg hemagglutinin from each strain with MF59 adjuvant. The immunogenicity of two intranasal doses, delivered by syringe as drops into both nostrils with an interval of 1 week between, was compared with that of two inoculations by intramuscular delivery 3 weeks apart. The intramuscular and intranasal vaccine formulations were bo...Continue Reading

References

Jan 1, 1979·British Medical Bulletin·C W Potter, J S Oxford
Oct 1, 1976·British Journal of Clinical Pharmacology·F Y Aoki, J C Crowley
May 1, 1985·The Journal of Pharmacy and Pharmacology·J G HardyC G Wilson
May 1, 1995·Infection and Immunity·C BergquistJ Holmgren
Apr 1, 1995·Trends in Microbiology·G P van den Dobbelsteen, E P van Rees
Jun 1, 1997·European Journal of Epidemiology·J S Ellis, M C Zambon
Sep 30, 1999·Drugs & Aging·E M Corrigan, R L Clancy
Oct 16, 1999·Lancet·N J Cox, K Subbarao
Nov 5, 1999·Advances in Virus Research·K Subbarao
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·F W van GinkelJ R McGhee
Feb 26, 2004·Statistics in Medicine·UNKNOWN Committee for Proprietary Medicinal Products (CPMP)
Feb 27, 2004·The New England Journal of Medicine·Margot MutschRobert Steffen

❮ Previous
Next ❯

Citations

Sep 22, 2009·Médecine sciences : M/S·Pierre Loulergue, Odile Launay
Oct 10, 2008·The New England Journal of Medicine·Iain StephensonAngelika Banzhoff
Nov 19, 2010·The New England Journal of Medicine·Linda C Lambert, Anthony S Fauci
May 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Grazia GalliIain Stephenson
Dec 9, 2008·American Journal of Clinical Oncology·Svetomir N MarkovicMark R Pittelkow
Mar 31, 2012·Clinical and Vaccine Immunology : CVI·Luigi BuonaguroFranco M Buonaguro
Oct 7, 2009·Expert Review of Vaccines·Franco Maria BuonaguroLuigi Buonaguro
Nov 16, 2012·Expert Review of Vaccines·Ayman GebrilValerie A Ferro
Oct 11, 2014·Viruses·Michael Schotsaert, Adolfo García-Sastre
Oct 13, 2007·Expert Review of Vaccines·Dorothea SesardicBrijesh Prakash Patel
Apr 8, 2009·Expert Review of Vaccines·Michael SchotsaertXavier Saelens
Sep 5, 2006·Expert Opinion on Drug Delivery·Hansi J Dean
Aug 9, 2007·Expert Opinion on Drug Delivery·Dmytro S SilinAldar S Bourinbaiar
Sep 21, 2007·Expert Opinion on Drug Delivery·Gideon Kersten, Hoang Hirschberg
Nov 3, 2010·Journal of Drug Targeting·Barbara C Baudner, Derek T O'Hagan
Nov 5, 2010·Journal of Drug Targeting·Inderjit Jabbal-Gill
Jul 29, 2008·Journal of Pharmaceutical Sciences·Sameer SharmaYan Chen
May 9, 2012·International Journal of Pharmaceutics·J F Correia-PintoM J Alonso
Jan 13, 2010·Vaccine·Ali M HarandiUNKNOWN Working Group convened by EUROPRISE
Jun 17, 2008·International Journal of Pharmaceutics·Yvonne PerrieVincent W Bramwell
Feb 5, 2008·Vaccine·Dubravka Grdic EliassonNils Lycke
Jul 18, 2009·European Journal of Immunology·Jeffrey D Ahlers, Igor M Belyakov
Jun 15, 2011·Influenza and Other Respiratory Viruses·Jessica C SeidmanMark A Miller
May 11, 2010·Immunological Investigations·Amit A LugadeYasmin Thanavala
Dec 10, 2008·International Reviews of Immunology·Petr O IlyinskiiAlexander M Shneider
Feb 26, 2009·International Reviews of Immunology·Thorsten Demberg, Marjorie Robert-Guroff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.